Literature DB >> 23811077

Comparative immunochemical characteristics of botulinum neurotoxin type A and its associated proteins.

Anne-Marie Bryant1, Shuowei Cai, Bal Ram Singh.   

Abstract

Clostridium botulinum strains secrete their neurotoxins (BoNT) along with a group of neurotoxin-associated proteins (NAPs) that enhance the oral toxicity and provide protection to the neurotoxin against acidity, temperature and proteases in the G.I. tract. A major component of NAPs is Hn-33, a 33 kDa protein, which is also protease resistant and strongly protects BoNT. The complex form of BoNT/A is used as a commercial therapeutic formulation against many neuromuscular disorders and for cosmetic purposes. Immune response against this formulation could hinder its long-term use; therefore, it is important to characterize the immunological properties of the associated proteins. This study aims to understand the immunological reactivity of BoNT/A complex, BoNT, NAPs, and Hn-33 through a series of competitive enzyme-linked immunosorbent assays (ELISA). The results indicated that BoNT/A complex competed 6 times more with complex antibodies compared to the neurotoxin confirming that the higher immunogenicity of BoNT/A complex was indeed a result of the associated proteins with the neurotoxin complex. While the nearly identical immuno-reactivity of BoNT/A complex and Hn-33 with Hn-33 antibodies indicated that the reactivity was due to the higher immunogenicity not the abundance of Hn-33 in the complex. Both the ELISA and immuno-blot results implied that Hn-33 is primarily responsible for eliciting the antibody response in BoNT/A complex.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  2,2′-Azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt; ABTS; BoNT; BoNT/A; Botulinum; Clostridium; Complex; ELISA; Hn-33; IgG; Immunogenicity; NAPs; NBP; PBS; PBST; TBST; Tris buffered saline containing 0.05% Tween-20; botulinum neurotoxin; botulinum neurotoxin type A; enzyme-linked immunosorbent assay; immunoglobulin G; neurotoxin-associated proteins; neurotoxin-binding protein; phosphate buffered saline; phosphate buffered saline containing 0.05% Tween-20

Mesh:

Substances:

Year:  2013        PMID: 23811077      PMCID: PMC5660946          DOI: 10.1016/j.toxicon.2013.06.011

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  12 in total

1.  Immunological properties of Hn-33 purified from type A Clostridium botulinum.

Authors:  S K Sharma; B R Singh
Journal:  J Nat Toxins       Date:  2000-11

Review 2.  The story of Clostridium botulinum: from food poisoning to Botox.

Authors:  Patricia T Ting; Anatoli Freiman
Journal:  Clin Med (Lond)       Date:  2004 May-Jun       Impact factor: 2.659

3.  A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia.

Authors:  R Benecke; W H Jost; P Kanovsky; E Ruzicka; G Comes; S Grafe
Journal:  Neurology       Date:  2005-06-14       Impact factor: 9.910

Review 4.  Botulism diagnostics: from clinical symptoms to in vitro assays.

Authors:  Shuowei Cai; Bal Ram Singh; Shashi Sharma
Journal:  Crit Rev Microbiol       Date:  2007 Apr-Jun       Impact factor: 7.624

Review 5.  Properties and use of botulinum toxin and other microbial neurotoxins in medicine.

Authors:  E J Schantz; E A Johnson
Journal:  Microbiol Rev       Date:  1992-03

6.  Immunological characterization of the subunits of type A botulinum neurotoxin and different components of its associated proteins.

Authors:  Roshan Kukreja; Tzuu-Wang Chang; Shuowei Cai; Paul Lindo; Stephen Riding; Yu Zhou; Easwaran Ravichandran; Bal Ram Singh
Journal:  Toxicon       Date:  2009-05       Impact factor: 3.033

7.  A protease-resistant novel hemagglutinin purified from type A Clostridium botulinum.

Authors:  F N Fu; S K Sharma; B R Singh
Journal:  J Protein Chem       Date:  1998-01

8.  Immunochemical characterization of type A botulinum neurotoxin in its purified and complexed forms.

Authors:  B R Singh; T Lopes; M A Silvia
Journal:  Toxicon       Date:  1996-02       Impact factor: 3.033

9.  Purification and amino acid composition of type A botulinum neurotoxin.

Authors:  B R DasGupta; V Sathyamoorthy
Journal:  Toxicon       Date:  1984       Impact factor: 3.033

10.  Molecular composition and extinction coefficient of native botulinum neurotoxin complex produced by Clostridium botulinum hall A strain.

Authors:  Anne-Marie Bryant; Jenny Davis; Shuowei Cai; Bal Ram Singh
Journal:  Protein J       Date:  2013-02       Impact factor: 2.371

View more
  8 in total

1.  Immunoprecipitation of native botulinum neurotoxin complexes from Clostridium botulinum subtype A strains.

Authors:  Guangyun Lin; William H Tepp; Marite Bradshaw; Chase M Fredrick; Eric A Johnson
Journal:  Appl Environ Microbiol       Date:  2014-10-31       Impact factor: 4.792

2.  Emerging Trends in Botulinum Neurotoxin A Resistance: An International Multidisciplinary Review and Consensus.

Authors:  Wilson W S Ho; Philipp Albrecht; Pacifico E Calderon; Niamh Corduff; David Loh; Michael U Martin; Je-Young Park; Lis S Suseno; Fang-Wen Tseng; Vasanop Vachiramon; Rungsima Wanitphakdeedecha; Chong-Hyun Won; Jonathan N T Yu; Mary Dingley
Journal:  Plast Reconstr Surg Glob Open       Date:  2022-06-20

3.  Immunogenicity Associated with Aesthetic Botulinumtoxin A: A Survey of Asia-Pacific Physicians' Experiences and Recommendations.

Authors:  Je-Young Park; Niamh Corduff; Jürgen Frevert; Rungsima Wanitphakdeedecha; Yates Y Y Chao
Journal:  Plast Reconstr Surg Glob Open       Date:  2022-04-18

4.  Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products.

Authors:  Jürgen Frevert
Journal:  Drugs R D       Date:  2015-03

Review 5.  Immunogenicity of Botulinum Toxin Formulations: Potential Therapeutic Implications.

Authors:  Warner W Carr; Neal Jain; J Wesley Sublett
Journal:  Adv Ther       Date:  2021-09-13       Impact factor: 3.845

6.  Comparison of neurotoxic potency between a novel chinbotulinumtoxinA with onabotulinumtoxinA, incobotulinumtoxinA and lanbotulinumtoxinA in rats.

Authors:  Ya Feng; Wuchao Liu; Lizhen Pan; Cong Jiang; Chengxi Zhang; Yuxuan Lu; Zhiyu Nie; Lingjing Jin
Journal:  Drug Des Devel Ther       Date:  2017-06-28       Impact factor: 4.162

7.  Neurotoxin Impurities: A Review of Threats to Efficacy.

Authors:  Je-Young Park; Owen Sunga; Rungsima Wanitphakdeedecha; Jürgen Frevert
Journal:  Plast Reconstr Surg Glob Open       Date:  2020-01-24

8.  Significant Long-Lasting Improvement after Switch to Incobotulinum Toxin in Cervical Dystonia Patients with Secondary Treatment Failure.

Authors:  Harald Hefter; Beyza Ürer; Raphaela Brauns; Dietmar Rosenthal; Sven G Meuth; John-Ih Lee; Philipp Albrecht; Sara Samadzadeh
Journal:  Toxins (Basel)       Date:  2022-01-06       Impact factor: 4.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.